Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study

被引：21
|
作者：
Wessels, Alette M. [1 ]
Bies, Robert R. [1 ,2 ]
Pollock, Bruce G. [2 ,3 ,4 ]
Schneider, Lon S. [5 ]
Lieberman, Jeffrey A. [6 ,9 ,10 ,11 ,12 ,13 ,14 ]
Stroup, Scott [6 ]
Li, Claire H. [1 ]
Coley, Kim [7 ]
Kirshner, Margaret M. [4 ]
Marder, Stephen R. [8 ,15 ,16 ,17 ,18 ,19 ,20 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN USA
[2] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada
[3] Univ Toronto, Baycrest Hosp, Rotman Res Inst, Toronto, ON, Canada
[4] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[5] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[6] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA
[7] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA
[8] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA
[9] GlaxoSmithKline, London, England
[10] Intracellular Therapies, New York, NY 10032 USA
[11] Eli Lilly & Co, Indianapolis, IN USA
[12] Pierre Fabre, Castres, France
[13] Psychogenics, Tarrytown, NY USA
[14] Wyeth, Madison, NJ USA
[15] Advisory Board Wyeth, Madison, NJ USA
[16] Otsuka, Tokyo, Japan
[17] Sanofi Aventis, Bombay, Maharashtra, India
[18] Lundbeck, Copenhagen, Denmark
[19] Pfizer, New York, NY USA
[20] Schering Plough Corp, Kenilworth, NJ 07033 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 11期
基金：
加拿大健康研究院;
关键词：
ziprasidone; population pharmacokinetics; schizophrenia; CLINICAL ANTIPSYCHOTIC TRIALS; PROJECT; IMPACT; DRUG; RACE;
D O I：
10.1177/0091270010387604
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：1587 / 1591
页数：5
相关论文
共 50 条
  • [31] Researchers study the effects of risperidone and ziprasidone on schizophrenia
    不详
    CNS SPECTRUMS, 2003, 8 (07) : 480 - 481
  • [32] Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder
    Versavel, M
    DelBello, MP
    Ice, K
    Kowatch, R
    Keller, D
    Miceli, J
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S122 - S123
  • [33] Substance use in persons with schizophrenia - Baseline prevalence and correlates from the NIMH CATIE study
    Swartz, MS
    Wagner, HR
    Swanson, JW
    Stroup, TS
    McEvoy, JP
    Canive, JM
    Miller, DD
    Reimherr, F
    McGee, M
    Khan, A
    Van Dorn, R
    Rosenheck, RA
    Lieberman, JA
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2006, 194 (03) : 164 - 172
  • [34] Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer
    Liao, Mingxiang
    Zhou, Jie
    Wride, Kenton
    Lepley, Denise
    Cameron, Terri
    Sale, Mark
    Xiao, Jim
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (05) : 711 - 723
  • [35] Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer
    Mingxiang Liao
    Jie Zhou
    Kenton Wride
    Denise Lepley
    Terri Cameron
    Mark Sale
    Jim Xiao
    European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47 : 711 - 723
  • [36] Population pharmacokinetic modeling for sotalol in pediatric patients with tachycardia
    Läer, S
    Elshoff, JP
    Zhang, W
    Meibohm, B
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S76 - S76
  • [37] Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients
    Esmaeili, Tayebeh
    Rezaee, Mahmood
    Abdar Esfahani, Morteza
    Davoudian, Azadeh
    Omidfar, Dariush
    Rezaee, Saeed
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (08) : 1284 - 1292
  • [38] Lessons from the CATIE Study
    Perkins, Diana O.
    CNS SPECTRUMS, 2006, : 14 - 15
  • [39] Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients
    Ji, Shuangmin
    Shang, Dewei
    Wu, Kehua
    Li, Anning
    Li, Xiwei
    Deng, Chenhui
    Li, Liang
    Zhou, Tianyan
    Wang, Chuanyue
    Lu, Wei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (05) : 378 - 389
  • [40] Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale
    Reddy, Venkatesh Pilla
    Kozielska, Magdalena
    Johnson, Martin
    Mafirakureva, Nyashadzaishe
    Vermeulen, An
    Liu, Jing
    de Greef, Rik
    Rujescu, Dan
    Groothuis, Geny M. M.
    Danhof, Meindert
    Proost, Johannes H.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (06) : 731 - 739
12345